These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 9384462

  • 1. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
    Lennard L, Welch JC, Lilleyman JS.
    Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
    [Abstract] [Full Text] [Related]

  • 2. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
    Lennard L, Cartwright CS, Wade R, Richards SM, Vora A.
    Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
    [Abstract] [Full Text] [Related]

  • 3. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
    Levinsen M, Rosthøj S, Nygaard U, Heldrup J, Harila-Saari A, Jonsson OG, Bechensteen AG, Abrahamsson J, Lausen B, Frandsen TL, Weinshilboum RM, Schmiegelow K.
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
    [Abstract] [Full Text] [Related]

  • 4. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
    Lennard L, Lewis IJ, Michelagnoli M, Lilleyman JS.
    Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
    [Abstract] [Full Text] [Related]

  • 5. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
    Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE.
    Blood; 1999 May 01; 93(9):2817-23. PubMed ID: 10216075
    [Abstract] [Full Text] [Related]

  • 6. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE.
    J Natl Cancer Inst; 1999 Dec 01; 91(23):2001-8. PubMed ID: 10580024
    [Abstract] [Full Text] [Related]

  • 7. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Nielsen SN, Toksvang LN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jónsson ÓG, Vaitkeviciene G, Pruunsild K, Appell ML, Hjalgrim LL, Schmiegelow K.
    Cancer Chemother Pharmacol; 2021 Aug 01; 88(2):271-279. PubMed ID: 33928426
    [Abstract] [Full Text] [Related]

  • 8. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T, Ebbesen M, Nersting J, Frandsen TL, Appell ML, Schmiegelow K.
    Cancer Chemother Pharmacol; 2018 Mar 01; 81(3):579-586. PubMed ID: 29387964
    [Abstract] [Full Text] [Related]

  • 9. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia.
    McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE.
    Blood; 1995 Apr 01; 85(7):1897-902. PubMed ID: 7703493
    [Abstract] [Full Text] [Related]

  • 10. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
    Pettersson B, Almer S, Albertioni F, Söderhäll S, Peterson C.
    Ther Drug Monit; 2002 Jun 01; 24(3):351-8. PubMed ID: 12021625
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
    Nielsen SN, Frandsen TL, Nersting J, Hjalgrim LL, Schmiegelow K.
    J Pediatr Hematol Oncol; 2015 Apr 01; 37(3):e206-9. PubMed ID: 25171455
    [Abstract] [Full Text] [Related]

  • 13. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia.
    McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, Eden OB, Hall AG, Gibson BE.
    Br J Haematol; 1999 Jun 01; 105(3):696-700. PubMed ID: 10354134
    [Abstract] [Full Text] [Related]

  • 14. Thiopurine methyltransferase: a review and a clinical pilot study.
    Keuzenkamp-Jansen CW, Leegwater PA, De Abreu RA, Lambooy MA, Bokkerink JP, Trijbels JM.
    J Chromatogr B Biomed Appl; 1996 Mar 29; 678(1):15-22. PubMed ID: 8861653
    [Abstract] [Full Text] [Related]

  • 15. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.
    Lennard L, Lilleyman JS.
    Ther Drug Monit; 1996 Aug 29; 18(4):328-34. PubMed ID: 8857546
    [Abstract] [Full Text] [Related]

  • 16. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
    Dervieux T, Médard Y, Verpillat P, Guigonis V, Duval M, Lescoeur B, Suciu S, Vilmer E, Jacqz-Aigrain E.
    Leukemia; 2001 Nov 29; 15(11):1706-12. PubMed ID: 11681411
    [Abstract] [Full Text] [Related]

  • 17. Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia.
    Chrzanowska M, Kuehn M, Januszkiewicz-Lewandowska D, Kurzawski M, Droździk M.
    Acta Pol Pharm; 2012 Nov 29; 69(3):405-10. PubMed ID: 22594254
    [Abstract] [Full Text] [Related]

  • 18. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
    Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM.
    Lancet; 1990 Jul 28; 336(8709):225-9. PubMed ID: 1973780
    [Abstract] [Full Text] [Related]

  • 19. TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia.
    Dreisig K, Brünner ED, Marquart HV, Helt LR, Nersting J, Frandsen TL, Jonsson OG, Taskinen M, Vaitkeviciene G, Lund B, Abrahamsson J, Lepik K, Schmiegelow K.
    Pediatr Hematol Oncol; 2021 Apr 28; 38(3):227-238. PubMed ID: 33205673
    [Abstract] [Full Text] [Related]

  • 20. [Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy].
    Gu LJ, Ye QD, Liang AB, Zhao JC, Xue HL, Tang YN, Chen J, Ye YC.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jan 28; 24(1):18-21. PubMed ID: 12679004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.